Exact Sciences Corp (EXAS) is a publicly traded Healthcare sector company. As of May 21, 2026, EXAS trades at $104.91 with a market cap of $20.03B and a P/E ratio of -95.37. EXAS moved -0.02% today. Year to date, EXAS is +56.63%; over the trailing twelve months it is +136.92%. Its 52-week range spans $38.81 to $104.98. Analyst consensus is buy with an average price target of $103.18. Rallies surfaces EXAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded EXAS stock?
Recent politician trading activity in EXAS includes disclosures from Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
EXAS Key Metrics
Key financial metrics for EXAS
Metric
Value
Price
$104.91
Market Cap
$20.03B
P/E Ratio
-95.37
EPS
$-1.10
Dividend Yield
0.00%
52-Week High
$104.98
52-Week Low
$38.81
Volume
21.56M
Avg Volume
0
Revenue (TTM)
$3.25B
Net Income
$-207.95M
Gross Margin
69.69%
Congressional Trades in EXAS
Josh Gottheimer sale EXAS on May 10, 2024 (amount: $15.00K) for Joint.
Recent politician trading activity in EXAS includes disclosures from Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in EXAS?
Yes. Rallies tracks politician and congressional stock disclosures for EXAS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is EXAS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EXAS. It does not provide personalized investment advice.
